Vertex Pharmaceuticals Inc Stock Forecast for 2023 - 2025 - 2030

Updated on 11/29/2023

Stock Rating
15
Price Target
$390.00
Consensus
Outperform
Upside
12.38%
Analysts
18
Stock Rating
15
Upside
12.38%
Analysts
18
Price Target
$390.00

Vertex Pharmaceuticals Inc Stock Forecast and Price Target

The average target price for Vertex Pharmaceuticals Inc's stock set by eighteen renowned analysts in recent months is $390.00, representing a potential upside of approximately 12.38% from its last closing price if met by 2024. This estimation is based on a high estimate of $456.00 and a low estimate of $314.00. Even if you are not interested in VRTX stock, it is still imperative to be aware of its competitors.

$390.00

12.38% Upside

Outperform
Outperform

Vertex Pharmaceuticals Inc Fair Value Forecast for 2023 - 2025 - 2030

In the last three years, Price for Vertex Pharmaceuticals Inc has grown by 179.17%, going from $149.61 to $417.68. In the coming year, analysts are expecting an increase in Fair Value, predicting it will reach $436.49 – an increase of 4.50%. Over the next eight years, experts anticipate that Fair Value growth for Vertex Pharmaceuticals Inc will be 52.76%.

2023 Fair Value Forecast
$436.49
2024 Fair Value Forecast
$452.49
2025 Fair Value Forecast
$487.86
2026 Fair Value Forecast
$523.22
2027 Fair Value Forecast
$536.98
2028 Fair Value Forecast
$570.38
2029 Fair Value Forecast
$602.66
2030 Fair Value Forecast
$638.03
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
LLY Stock Forecast Eli Lilly & Co Outperform 16
$591.60 Buy/Sell $594.01 9.87%
JNJ Stock Forecast Johnson & Johnson Outperform 10
$151.63 Buy/Sell $176.14 13.43%
MRK Stock Forecast Merck Outperform 5
$100.18 Buy/Sell $123.75 24.78%
PFE Stock Forecast Pfizer Inc Outperform 3
$29.69 Buy/Sell $40.55 26.31%
BMY Stock Forecast Bristol-Myers Squibb Co Outperform 2
$48.92 Buy/Sell $64.26 25.72%

Vertex Pharmaceuticals Inc Revenue Forecast for 2023 - 2025 - 2030

In the last three years, Revenue for Vertex Pharmaceuticals Inc has grown by 114.54%, going from $4.16B to $8.93B. In the coming year, analysts are expecting an increase in Revenue, predicting it will reach $9.24B – an increase of 3.42%. Over the next eight years, experts anticipate that Revenue growth for Vertex Pharmaceuticals Inc will be 43.87%.

2023 Rev Forecast
$9.24B
2024 Rev Forecast
$9.72B
2025 Rev Forecast
$10.41B
2026 Rev Forecast
$11.03B
2027 Rev Forecast
$11.38B
2028 Rev Forecast
$11.90B
2029 Rev Forecast
$12.41B
2030 Rev Forecast
$12.85B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
REGN Stock Forecast Regeneron Pharmaceuticals Inc Outperform 2
$801.14 Buy/Sell $796.73 14.09%
ZTS Stock Forecast Zoetis Inc Outperform 18
$176.97 Buy/Sell $217.57 18.66%
ALNY Stock Forecast Alnylam Pharmaceuticals Inc Outperform 7
$161.36 Buy/Sell $245.24 42.54%

Vertex Pharmaceuticals Inc Dividend per Share Forecast for 2023 - 2025 - 2030

2023 DPS Forecast
$0.00
2024 DPS Forecast
$0.00
2025 DPS Forecast
$0.00
2026 DPS Forecast
$0.00
2027 DPS Forecast
$0.00
2028 DPS Forecast
$0.00
2029 DPS Forecast
$0.00
2030 DPS Forecast
$0.00
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BAX Stock Forecast Baxter International Inc Outperform 17
$36.34 Buy/Sell $45.50 22.45%
VTRS Stock Forecast Viatris Inc Hold 8
$9.14 Buy/Sell $11.74 25.82%
UTHR Stock Forecast United Therapeutics Corp Outperform 12
$230.39 Buy/Sell $278.82 30.21%

Vertex Pharmaceuticals Inc Free Cash Flow Forecast for 2023 - 2025 - 2030

In the last three years, Vertex Pharmaceuticals Inc's Free Cash Flow has grown, increasing from $1.49B to $3.89B – an increase of 160.72%. According to 7 prominent analysts, Vertex Pharmaceuticals Inc's Free Cash Flow will fall by 1.41% in the next year, reaching $3.84B. Over the next eight years, the pros' prediction is Free Cash Flowof $6.40B, which would mean a eight-year growth forecast of 64.22%.

2023 FCF Forecast
$3.84B
2024 FCF Forecast
$4.17B
2025 FCF Forecast
$4.44B
2026 FCF Forecast
$4.75B
2027 FCF Forecast
$5.09B
2028 FCF Forecast
$5.36B
2029 FCF Forecast
$6.02B
2030 FCF Forecast
$6.40B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
IONS Stock Forecast Ionis Pharmaceuticals Inc Outperform 9
$48.34 Buy/Sell $51.20 24.12%
CTLT Stock Forecast Catalent Outperform 15
$39.46 Buy/Sell $49.29 21.64%
PRGO Stock Forecast Perrigo Co PLC Outperform 16
$30.46 Buy/Sell $45.67 44.45%

Vertex Pharmaceuticals Inc Net Income Forecast for 2023 - 2025 - 2030

In the last three years, Vertex Pharmaceuticals Inc's Net Income has increased by 182.29%, going from $1.18B to $3.32B. In the next year, analysts are expecting an increase in Net Income, predicting it will reach $4.05B – an increase of 22.04%. The Vertex Pharmaceuticals Inc forecast is for Net Income to reach $6.01B or grow by 80.89%.

2023 NI Forecast
$4.05B
2024 NI Forecast
$4.21B
2025 NI Forecast
$4.48B
2026 NI Forecast
$4.83B
2027 NI Forecast
$5.02B
2028 NI Forecast
$5.37B
2029 NI Forecast
$5.71B
2030 NI Forecast
$6.01B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BCPC Stock Forecast Balchem Outperform 18
$122.71 Buy/Sell $145.00 22.24%
MDGL Stock Forecast Madrigal Pharmaceuticals Outperform 4
$190.94 Buy/Sell $170.08 73.09%
NEOG Stock Forecast Neogen Outperform 16
$16.60 Buy/Sell $37.00 34.04%

Vertex Pharmaceuticals Inc EBITDA Forecast for 2023 - 2025 - 2030

Vertex Pharmaceuticals Inc's EBITDA has increased by 245.84% In the last three years, going from $1.31B to $4.53B. In the next year, analysts expect EBITDA to reach $5.57B – an increase of 22.96%. For the next eight years, the forecast is for EBITDA to grow by 28.19%.

2023 EBITDA Forecast
$5.57B
2024 EBITDA Forecast
$5.94B
2025 EBITDA Forecast
$6.23B
2026 EBITDA Forecast
$5.61B
2027 EBITDA Forecast
$5.61B
2028 EBITDA Forecast
$5.73B
2029 EBITDA Forecast
$5.90B
2030 EBITDA Forecast
$5.80B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
CYTK Stock Forecast Cytokinetics Inc Outperform 10
$31.22 Buy/Sell $61.75 92.18%
AMPH Stock Forecast Amphastar Pharmaceuticals Outperform 14
$54.41 Buy/Sell $69.00 21.30%
CORT Stock Forecast Corcept Therapeutics Outperform 16
$25.45 Buy/Sell $0.00 41.45%

Vertex Pharmaceuticals Inc EBIT Forecast for 2023 - 2025 - 2030

In the last three years, Vertex Pharmaceuticals Inc's EBIT has grown, increasing from $1.20B to $4.38B – a growth of 264.26%. The next year looks promising for Vertex Pharmaceuticals Inc, with analysts predicting EBIT of $5.07B – an increase of 15.83%. Over the next eight years, experts anticipate that Vertex Pharmaceuticals Inc's EBIT will grow at a rate of 66.85%.

2023 EBIT Forecast
$5.07B
2024 EBIT Forecast
$5.18B
2025 EBIT Forecast
$5.44B
2026 EBIT Forecast
$5.82B
2027 EBIT Forecast
$6.20B
2028 EBIT Forecast
$6.57B
2029 EBIT Forecast
$6.92B
2030 EBIT Forecast
$7.31B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
INDV Stock Forecast Indivior PLC Buy 14
£12.38 Buy/Sell £3.79 134.25%
TGTX Stock Forecast TG Therapeutics Outperform 9
$12.63 Buy/Sell $26.83 90.02%
CPRX Stock Forecast Catalyst Pharmaceuticals Outperform 16
$14.21 Buy/Sell $23.30 75.93%

Vertex Pharmaceuticals Inc EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last three years, EPS for Vertex Pharmaceuticals Inc has grown by 179.17%, going from $5.33 to $14.88. In the coming year, analysts are expecting an increase in EPS, predicting it will reach $15.55 – an increase of 4.50%. Over the next eight years, experts anticipate that EPS growth for Vertex Pharmaceuticals Inc will be 52.76%.

2023 EPS Forecast
$15.55
2024 EPS Forecast
$16.12
2025 EPS Forecast
$17.38
2026 EPS Forecast
$18.64
2027 EPS Forecast
$19.13
2028 EPS Forecast
$20.32
2029 EPS Forecast
$21.47
2030 EPS Forecast
$22.73
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
IRWD Stock Forecast Ironwood Pharmaceuticals Outperform 14
$9.68 Buy/Sell $17.40 106.61%
SUPN Stock Forecast Supernus Pharmaceuticals Outperform 16
$26.97 Buy/Sell $41.00 53.87%
ARPO Stock Forecast Aerpio Pharmaceuticals - 6
$30.30 Buy/Sell $0.00 -100.00%